New drug approvals in prostate cancer and their effect on the treatment landscape.

Jani, Chinmay; Abdallah, Nour; Chrysafi, Pavlina; Mouchati, Christian; Herchenhorn, Daniel; McKay, Rana R

Jani, Chinmay; Abdallah, Nour; Chrysafi, Pavlina; Mouchati, Christian; Herchenhorn, Daniel; McKay, Rana R.

Afiliación

Jani C; Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts.
Abdallah N; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Chrysafi P; Department of Urology Research, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Mouchati C; Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts.
Herchenhorn D; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
McKay RR; School of Medicine, Case Western Reserve University, Cleveland, Ohio.

Clin Adv Hematol Oncol ; 21(6): 321-340, 2023 Jun.

Article en En | MEDLINE | ID: mdl-37530638

Asunto(s)

Antineoplásicos; Neoplasias de la Próstata Resistentes a la Castración; Masculino; Humanos; Neoplasias de la Próstata Resistentes a la Castración/patología; Antagonistas de Andrógenos/uso terapéutico; Aprobación de Drogas; Antineoplásicos/efectos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / Antineoplásicos Límite: Humans / Male Idioma: En Revista: Clin Adv Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links